Radiomer Therapeutics, a Houston, TX-based Fannin Partners-founded company that is developing targeted radiopharmaceuticals / radioligand therapies for theranostic applications, has been launched with undisclosed pre-seed funding.
The company intends to use the funds to continue development of its radiopharmaceutical/ radioligand therapy platform and programs.
Led by Atul Varadhachary, MD, PhD, CEO, and Phil Breitfeld, MD, Chief Medical Officer, Radiomer leverages Fannin’s proprietary RaptamerTM platform as targeting vectors/ligands for theranostic application. A Raptamer is a novel targeting agent that consists of a single-stranded (ss) DNA backbone decorated with peptide-like side chains to add chemical diversity and improve binding affinity. The modular Raptamer structure allows the addition of a variety of linkers, chelators and isotope payloads.
Radiomer has a rich pipeline of assets in development with lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in Q1 2025. Lead programs address major cancers including breast, lung, colorectal, prostate, and head and neck cancers.
Created in 2023, Radiomer Therapeutics operated in stealth during the past year, generating data using the rights to radiopharmaceutical applications for Fannin’s Raptamer targeting platform, which has been in the portfolio since 2019.
Established in 2014, Houston-based Fannin is among the most active early-stage product development groups in the life sciences with a dozen programs/ platforms at different stages of development. Fannin advances its pipeline both internally and through Fannin-founded entities with a combination of investor and grant funding. In the last decade, Fannin has brought in ~35 programs, of which a dozen are active including three in the clinic. Collectively, ~$242m has been invested across Fannin programs, $71M from grant funding and $171M from investors.
FinSMEs
30/05/2024